MBMary T. Bessesen

Mary T. Bessesen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mary T. Bessesen has a total of 144 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of a Three-Strain Lactobacilli Probiotic (BioK+) on Incidence of Hospital-Onset Clostridioides difficile: A Retrospective Observational Cohort Study

    by Matthew A. Jenest, Randolph V. Fugit, Jason Wright, Mary T. Bessesen, Shelley E. Kon

    Background: Prevention of hospital-onset Clostridioides difficile infection (HO-CDI) is a priority for hospitals. In addition to standard infection control measures, some probiotics show promise in reducing HO-CDI incidence. However, prior research has produced mixed results. Methods: Retrospective, observational cohort study of HO-CDI incidence among inpatients treated with or without BioK+ probiotic prophylaxis. BioK+, a probiotic with three Lactobacilli strains, was administered to patients on antibiotics with high risk for HO-CDI. BioK+ was continued for 5 days after antibiotics were discontinued, or the patient was discharged. The primary outcome was HO-CDI incidence. Results: Out of 494 eligible patients on high-risk antibiotics, 343 patients received BioK+ probiotics. No cases of HO-CDI were identified in patients who received BioK+, compared to three cases among patients not on BioK+ (p = 0.028). In the baseline period (1 April 2021–31 March 2022) the HO-CDI incidence density was 5.62 per 10,000 bed-days. In the BioK+ probiotic period (1 April 2022–31 March 2023), the incidence density was 2.22 cases per 10,000 patient days (p = 0.03). Conclusions: When bundled with standard infection control practices, the use of BioK+ probiotics was associated with a statistically significant decreased incidence of HO-CDI among patients prescribed high-risk antibiotics.


  • Open Access

    Pilot of a bowel habit assessment tool to enable early identification of Clostridioides difficile infection

    by Shelley E. Kon, Christine Gunter, Heidi Hough, Randi Craig, Ashley M. Lane, Mary T. Bessesen

    Objective: To develop a symptom assessment tool to assist health care providers with discussing bowel habits in a sensitive and accurate method. Design: Pre and Post education survey. Setting: 180 bed academically affiliated Veterans Affairs Hospital. Participants: Nurses, nursing assistants and physicians who participated in a brief educational session. Methods: A Bowel Habits Assessment Tool (BHAT) was developed to assist health care providers in learning skills to assess patient bowel habits accurately. The BHAT was introduced at educational sessions. An anonymous pre and post survey employing a 5-point Likert scale was administered to participants. Results: Pre-educational session survey results for Question 1 (Q1) “I am comfortable discussing patient’s bowel habits included: 4.6% strongly disagreed or somewhat disagreed, 3% neither agreed nor disagreed, 20% somewhat agreed and 72.3% strongly agreed. After the BHAT education, 100% (n=65) of participants strongly agreed or somewhat agreed that they were comfortable discussing patient’s bowel habits. Q1 pre/post mean difference 0.25 (CI 0.06539 - 0.4269, p = 0.0084). On the pre-survey, only 34% of participants strongly agreed that they were aware of tools to help discuss patients’ bowel habits. This increased to 77% after the BHAT educational session. (Q2). Q2 pre/post mean difference 1.02 (CI 0.7366 - 1.294, p Clostridioides difficile in a timely manner.

  • Open Access

    Procalcitonin for sepsis management: Implementation within an antimicrobial stewardship program

    by Randolph V Fugit, John B M McCoury, Mary T Bessesen

    In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. Clinical trials of procalcitonin (PCT)–based algorithms for antibacterial therapy have shown a reduction in antimicrobial use and improved survival. Translation of PCT algorithms to clinical settings has often been unsuccessful. We hypothesized that appropriate utilization of PCT could be improved by implementing an antimicrobial stewardship team (AST) approach to PCT testing. We completed a pre-post intervention evaluation of adult patients admitted to the intensive care unit with a diagnosis of sepsis. The standard PCT algorithm period (SPAP) cohort included patients enrolled before dedicated AST involvement. During the AST-supported PCT algorithm period (ASPAP), the AST reviewed and provided feedback for all appropriate patients. The primary outcome was adherence to the PCT algorithm. Thirty-five and 57 patients were evaluated in the SPAP and ASPAP cohorts, respectively. There were no differences in demographics or infection site between the groups. Baseline PCT assessment was ordered in a larger proportion of patients in the ASPAP cohort (90% vs 57%; P = 0.0006). Follow-up PCT measurement was performed in more patients in the ASPAP cohort (76% vs 23%; P < 0.0001). Antibiotics were discontinued per algorithm in more patients in the ASPAP cohort (25/57 [44%] vs 2/35 [7%]; P < 0.0001). Patients in the ASPAP cohort experienced a shorter total duration of antibiotics (5 vs 7 days; P = 0.02), with no significant difference in length of stay or 30-day readmission or mortality between the cohorts. A PCT algorithm successfully implemented by an AST was associated with a significant decrease in total antibiotic days with no differences in mortality or length of stay.


  • Open Access

    Outcomes of Limb-Sparing Surgery for Osteomyelitis in the Diabetic Foot: Importance of the Histopathologic Margin

    by Matthew J Johnson, Nathan Shumway, Mark Bivins, Mary T Bessesen

    Background: Diabetes mellitus affects up to 14% of Americans. Infection of the diabetic foot is a common complication, which may lead to amputation. If infection extends to involve bone, the risk of amputation is increased 4-fold. Presence of osteomyelitis at the histopathologic margin of resection portends a poor prognosis in osteomyelitis outside the setting of the diabetic foot. We aimed to assess the association of a positive histopathologic margin with the outcome of osteomyelitis in the diabetic foot. Methods: Medical records were reviewed for all patients who underwent below-ankle amputation for osteomyelitis of the diabetic foot. Patients who had at least 1 year of follow-up, a histopathologic diagnosis of osteomyelitis, and a comment on whether the margin was involved were included. Results: Thirty-nine of 66 (59%) cases had remission of osteomyelitis at 12 months. When comparing cases with remission with those who experienced recurrence in the 12 months of follow-up, there were no statistically significant differences in age, glycosylated hemoglobin, duration of antimicrobial therapy, Infectious Diseases Society of America class, or presence of osteomyelitis at the histopathologic margin. Among cases with a negative histopathologic margin, 29/48 (60.4%) were free of disease at 1 year, compared with 10/18 (55.6%) cases with a positive histopathologic margin (P = .72). Remission was significantly more frequent in cases undergoing amputation at the digit level (66.7%) compared with amputation at the metatarsal level (40.7%) (P = .045). Conclusions: Osteomyelitis of the diabetic foot at the histopathologic margin of resection was not associated with increased risk of treatment failure. Resection at the level of the digit was associated with a lower risk of failure than at the metatarsal level.


  • Open Access

    Genomic evolution of Staphylococcus aureus isolates colonizing the nares and progressing to bacteremia

    by Jeanne B Benoit, Daniel N Frank, Mary T Bessesen

    Nasal colonization by Staphylococcus aureus is a key risk factor for bacteremia. The objective of this study is to identify genomic modifications occurring in nasal carriage strains of S. aureus as they progress to bacteremia in a cohort of hospitalized patients. Eight patients with S. aureus bacteremia were identified. Genomic sequences of the bloodstream isolates were compared with 57 nasal isolates collected longitudinally prior to the occurrence of bacteremia, which covered a timespan of up to 326 days before bacteremia. Within each subject, nasal colonizing strains were closely related to bacteremia strains. Within a subject, the number of single nucleotide polymorphisms (SNPs) observed between time points was greater than within a single time point. Co-colonization and strain replacement were observed in one case. In all cases colonization progressed to bacteremia without addition of new virulence genes. In one case, a mutation in the accessory gene regulator gene caused abrogation of agr function. S. aureus evolves in the human nares at a variable rate. Progression of S. aureus nasal colonization to nosocomial infection is seldom associated with acquisition of new virulence determinants. Mutation in the agr gene with abrogation of function was associated with progression to bacteremia in one case.


  • High Adherence to HIV Pre-Exposure Prophylaxis among Veterans

    by Misha Huang, Wenhui Liu, Mary E. Plomondon, Allan V. Prochazka, Mary T. Bessesen


  • Open Access

    The Respiratory Protection Effectiveness Clinical Trial (ResPECT): a cluster-randomized comparison of respirator and medical mask effectiveness against respiratory infections in healthcare personnel

    by Lewis J. Radonovich, Mary T. Bessesen, Derek A. Cummings, Aaron Eagan, Charlotte Gaydos, Cynthia Gibert, Geoffrey J. Gorse, Ann-Christine Nyquist, Nicholas G. Reich, Maria Rodrigues-Barradas, et al.

    Although N95 filtering facepiece respirators and medical masks are commonly used for protection against respiratory infections in healthcare settings, more clinical evidence is needed to understand the optimal settings and exposure circumstances for healthcare personnel to use these devices. A lack of clinically germane research has led to equivocal, and occasionally conflicting, healthcare respiratory protection recommendations from public health organizations, professional societies, and experts. The Respiratory Protection Effectiveness Clinical Trial (ResPECT) is a prospective comparison of respiratory protective equipment to be conducted at multiple U.S. study sites. Healthcare personnel who work in outpatient settings will be cluster-randomized to wear N95 respirators or medical masks for protection against infections during respiratory virus season. Outcome measures will include laboratory-confirmed viral respiratory infections, acute respiratory illness, and influenza-like illness. Participant exposures to patients, coworkers, and others with symptoms and signs of respiratory infection, both within and beyond the workplace, will be recorded in daily diaries. Adherence to study protocols will be monitored by the study team. ResPECT is designed to better understand the extent to which N95s and MMs reduce clinical illness among healthcare personnel. A fully successful study would produce clinically relevant results that help clinician-leaders make reasoned decisions about protection of healthcare personnel against occupationally acquired respiratory infections and prevention of spread within healthcare systems. The trial is registered at clinicaltrials.gov, number NCT01249625 (11/29/2010).